论文部分内容阅读
目的观察脑梗死患者应用依达拉奉对血清高敏C反应蛋白(hs-CRP)、肿瘤坏死因子(TNF-α)水平的影响。方法50例急性脑梗死患者,随机分为治疗组(依达拉奉+常规治疗)和对照组(常规治疗),于治疗前和治疗后10d检测血清高敏C反应蛋白、肿瘤坏死因子水平,并对治疗前、后的数据进行比较。结果两组急性脑梗死患者血清hs-CRP和TNF-α水平在治疗前均高于健康体检组,差异具有统计学意义;而两组间比较差异无统计学意义。治疗后两组患者血清hs-CRP和TNF-α水平均下降,治疗组下降明显,与对照组相比差异具有统计学意义。结论监测血清hs-CRP和TNF-α水平有助于判断脑梗死的预后;应用依达拉奉治疗可以显著降低患者血清血清hs-CRP和TNF-α水平,从而减轻脑组织损伤,有利于脑梗死患者的转归。
Objective To observe the effect of edaravone on serum hs-CRP and TNF-α in patients with cerebral infarction. Methods Fifty patients with acute cerebral infarction were randomly divided into treatment group (edaravone + conventional treatment) and control group (conventional treatment). Serum high-sensitivity C-reactive protein and tumor necrosis factor level were measured before treatment and 10 days after treatment The data before and after treatment were compared. Results The serum levels of hs-CRP and TNF-α in two groups of patients with acute cerebral infarction before treatment were all significantly higher than those in the healthy group (P <0.05). There was no significant difference between the two groups. Serum levels of hs-CRP and TNF-α in both groups decreased after treatment, and the treatment group decreased significantly compared with the control group, the difference was statistically significant. Conclusion Monitoring serum hs-CRP and TNF-α levels may be helpful in judging the prognosis of cerebral infarction. The application of edaravone can significantly reduce the level of hs-CRP and TNF-α in serum of patients and thus reduce the damage of brain tissue and brain The outcome of infarction patients.